Chemokine-receptor interactions: GPCRS, glycosaminoglycans and viral chemokine binding proteins

Advances in Protein Chemistry

Volumn 68, Issue , 2004, Pages 351-391

  Lau, Elaine K ^a   Allen, Samantha ^a   Hsu, Andro R ^a   Handel, Tracy M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CHEMOKINE RECEPTOR; GLYCOSAMINOGLYCAN; VIRUS PROTEIN; CHEMOKINE; G PROTEIN COUPLED RECEPTOR;

CELL DAMAGE; CELL PROTECTION; IMMUNE SYSTEM; LYMPHOCYTE; ORGANOGENESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; HUMAN; PHYSIOLOGY; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHEMOKINES; GLYCOSAMINOGLYCANS; HUMANS; MODELS, BIOLOGICAL; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CHEMOKINE; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL PROTEINS;

EID: 16544379697     PISSN: 00653233     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-3233(04)68010-7     Document Type: Article

References (161)

1. Abdulaev, N. G., Strassmaier, T. T., Ngo, T., Chen, R., Luecke, H., Oprian, D. D., and Ridge, K. D. (2002). Grafting segments from the extracellular surface of CCR5 onto a bacteriorhodopsin transmembrane scaffold confers HIV-1 coreceptor activity. Structure (Camb) 10, 515-525.
2. Aiello, R. J., Bourassa, P. A., Lindsey, S., Weng, W., Natoli, E., Rollins, B. J., and Milos, P. M. (1999). Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb. Vasc. Biol. 19, 1518-1525.
3. Albini, A., Ferrini, S., Benelli, R., Sforzini, S., Giunciuglio, D., Aluigi, M. G., Proudfoot, A. E., Alouani, S., Wells, T. N., Mariani, G., Rabin, R. L., Farber, J. M., and Noonan, D. M. (1998). HIV-1 Tat protein mimicry of chemokines. Proc. Natl. Acad. Sci. USA 95, 13153-13158.
4. Alexander, J. M., Nelson, C. A., van Berkel, V., Lau, E. K., Studts, J. M., Brett, T. J., Speck, S. H., Handell, T. M., Virgin, H. W., and Fremont, D. H. (2002). Structural basis of chemokine sequestration by a herpesvirus decoy receptor. Cell 111, 343-356.
5. Ali, S., Palmer, A. C., Banerjee, B., Fritchley, S. J., and Kirby, J. A. (2000). Examination of the function of RANTES, MIP-1alpha, and MIP-1beta following interaction with heparin-like glycosaminoglycans. J. Biol. Chem. 275, 11721-11727.
6. Alon, R., Grabovsky, V., and Feigelson, S. (2003). Chemokine induction of integrin adhesiveness on rolling and arrested leukocytes local signaling events or global stepwise activation? Microcirculation 10, 297-311.
7. Appay, V., Brown, A., Cribbes, S., Randle, E., and Czaplewski, L. G. (1999). Aggregation of RANTES is responsible for its inflammatory properties. Characterization of non-aggregating, noninflammatory RANTES mutants. J. Biol. Chem. 274, 27505-27512.
8. Bacon, K., Baggiolini, M., Broxmeyer, H., Horuk, R., Lindley, L., Mantovani, A., Maysushima, K., Murphy, P., Nomiyama, H., Oppenheim, J., Rot, A., Schall, T., Tsang, M., Thorpe, R., Van Damme, J., Wadhwa, M., Yoshie, O., Zlotnik, A., and Zoon, K. (2002). Chemokine/chemokine receptor nomenclature. J. Interferon Cytokine Res. 22, 1067-1068.
9. Baggiolini, M. (1998). Chemokines and leukocyte traffic. Nature 392, 565-568.
10. Baggiolini, M. (2001). Chemokines in pathology and medicine. J. Intern. Med. 250, 91-104.
11. Baggiolini, M., Boulay, F., Badwey, J. A., and Curnutte, J. T. (1993). Activation of neutrophil leukocytes: Chemoattractant receptors and respiratory burst. FASEB J. 7, 1004-1010.
12. Baggiolini, M., Deranleau, D. A., Dewald, B., Thelen, M., von Tscharner, V., and Wymann, M. P. (1989). [Properties and activation mechanism of neutrophilic leukocytes]. Arzneimittelforschung 39, 177-180.
13. Baggiolini, M., Dewald, B., and Moser, B. (1997). Human chemokines: An update. Annu. Rev. Immunol. 15, 675-705.
14. Baggiolini, M., and Wymann, M. P. (1990). Turning on the respiratory burst. Trends Biochem. Sci. 15, 69-72.
15. Bai, M. (2004). Dimerization of G-protein-coupled receptors: Roles in signal transduction. Cell Signal. 16, 175-186.
16. Baird, J. W., Nibbs, R. J., Komai-Koma, M., Connolly, J. A., Ottersbach, K., Clark-Lewis, I., Liew, F. Y., and Graham, G. J. (1999). ESkine, a novel beta-chemokine, is differentially spliced to produce secretable and nuclear targeted isoforms. J. Biol. Chem. 274, 33496-33503.
17. Bajetto, A., Bonavia, R., Barbero, S., Florio, T., and Schettini, G. (2001). Chemokines and their receptors in the central nervous system. Front Neuroendocrinol. 22, 147-184.
18. Ben-Baruch, A. (2003). Host microenvironment in breast cancer development: Inflammatory cells, cytokines and chemokines in breast cancer progression: Reciprocal tumor-microenvironment interactions. Breast Cancer Res. 5, 31-36.
19. Benelli, R., Barbero, A., Ferrini, S., Scapini, P., Cassatella, M., Bussolino, F., Tacchetti, C., Noonan, D. M., and Albini, A. (2000). Human immunodeficiency virus transactivator protein (Tat) stimulates chemotaxis, calcium mobilization, and activation of human polymorphonuclear leukocytes: Implications for Tat-mediated pathogenesis. J. Infect. Dis. 182, 1643-1651.
20. Blanpain, C., Doranz, B. J., Bondue, A., Govaerts, C., De Leener, A., Vassart, G., Doms, R. W., Proudfoot, A., and Parmentier, M. (2003). The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J. Biol. Chem. 278, 5179-5187.
21. Blaszczyk, J., Coillie, E. V., Proost, P., Damme, J. V., Opdenakker, G., Bujacz, G. D., Wang, J. M., and Ji, X. (2000). Complete crystal structure of monocyte chemotactic protein-2, a CC chemokine that interacts with multiple receptors. Biochem. 39, 14075-14081.
22. Booth, V., Keizer, D. W., Kamphuis, M. B., Clark-Lewis, I., and Sykes, B. D. (2002). The CXCR3 binding chemokine IP-10/CXCL10: Structure and receptor interactions. Biochem. 41, 10418-10425.
23. Boring, L., Gosling, J., Cleary, M., and Charo, I. F. (1998). Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394, 894-897.
24. Breitwieser, G. E. (2004). G protein-coupled receptor oligomerization: Implications for G protein activation and cell signaling. Circ. Res. 94, 17-27.
25. Brigati, C., Giacca, M., Noonan, D. M., and Albini, A. (2003). HIV Tat, its TARgets and the control of viral gene expression. FEMS Microbiol. Lett. 220, 57-65.
26. Butcher, E. C., and Picker, L. J. (1996). Lymphocyte homing and homeostasis. Science 272, 60-66.
27. Capila, I., and Linhardt, R. J. (2002). Heparin-protein interactions. Angew. Chem. Int. Ed. Engl. 41, 391-412.
28. Clark-Lewis, I., Dewald, B., Loetscher, M., Moser, B., and Baggiolini, M. (1994). Structural requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids. J. Biol. Chem. 269, 16075-16081.
29. Clark-Lewis, I., Mattioli, I., Gong, J. H., and Loetscher, P. (2003). Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J. Biol. Chem. 278, 289-295.
30. Clore, G., Appella, M. E., Yamada, M., Matsushima, K., and Gronenborn, A. M. (1990). Three-dimensional structure of interleukin 8 in solution. Biochem. 29, 1689-1696.
31. Crump, M. P., Rajarathnam, K., Kim, K. S., Clark-Lewis, I., and Sykes, B. D. (1998). Solution structure of eotaxin, a chemokine that selectively recruits eosinophils in allergic inflammation. J. Biol. Chem. 273, 22471-22479.
32. D'Ambrosio, D., Panina-Bordignon, P., and Sinigaglia, F. (2003). Chemokine receptors in inflammation: An overview. J. Immunol. Methods 273, 3-13.
33. Datta, A., and Stone, M. J. (2003). Soluble mimics of a chemokine receptor: Chemokine binding by receptor elements juxtaposed on a soluble scaffold. Protein Sci. 12, 2482-2491.
34. Dawson, T. C., Lentsch, A. B., Wang, Z., Cowhig, J. E., Rot, A., Maeda, N., and Peiper, S. C. (2000). Exaggerated response to endotoxin in mice lacking the Duffy antigen/receptor for chemokines (DARC). Blood 96, 1681-1684.
35. DeLano, W. L. (2002). The PyMOL Molecular Graphics System. DeLano Scientific, San Carlos, CA.
36. Devalaraja, M. N., and Richmond, A. (1999). Multiple chemotactic factors: Fine control or redundancy? Trends Pharmacol. Sci. 20, 151-156.
37. Doranz, B. J., Grovit-Ferbas, K., Sharron, M. P., Mao, S. H., Goetz, M. B., Daar, E. S., Doms, R. W., and O'Brien, W. A. (1997). A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med. 186, 1395-1400.
38. Dowsland, M. H., Harvey, J. R., Lennard, T. W., Kirby, J. A., and Ali, S. (2003). Chemokines and breast cancer: A gateway to revolutionary targeted cancer treatments? Curr. Med. Chem. 10, 579-592.
39. Dragic, T., Trkola, A., Thompson, D. A., Cormier, E. G., Kajumo, F. A., Maxwell, E., Lin, S. W., Ying, W., Smith, S. D., Sakmar, T. P., and Moore, J. P. (2000). A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. USA 97, 5639-5644.
40. Duensing, T. D., Wing, J. S., and van Putten, J. P. (1999). Sulfated polysaccharide-directed recruitment of mammalian host proteins: A novel strategy in microbial pathogenesis. Infect. Immun. 67, 4463-4468.
41. Dwir, O., Grabovsky, V., Alon, R., and Feigelson, S. (2004). Selectin acidity modulation by chemokines at subsecond endothelial contacts: A novel regulatory level of leukocyte trafficking. Ernst. Schering. Res. Found Workshop 10, 109-135.
42. Egashira, K. (2003). Molecular mechanisms mediating inflammation in vascular disease: Special reference to monocyte chemoattractant protein-1. Hypertension 41, 834-841.
43. Farzan, M., Babcock, G. J., Vasilieva, N., Wright, P. L., Kiprilov, E., Mirzabekov, T., and Choe, H. (2002). The role of post-translational modifications of the CXCR4 amino terminus in stromal-derived factor 1 alpha association and HIV-1 entry. J. Biol. Chem. 277, 29484-29489.
44. Farzan, M., Mirzabekov, T., Kolchinsky, P., Wyatt, R., Cayabyab, M., Gerard, N. P., Gerard, C., Sodroski, J., and Choe, H. (1999). Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 96, 667-676.
45. Fong, A. M., Alam, S. M., Imai, T., Haribabu, B., and Patel, D. D. (2002). CX3CR1 tyrosine sulfation enhances fractalkine-induced cell adhesion. J. Biol. Chem. 277, 19418-19423.
46. Gerard, C., and Rollins, B. J. (2001). Chemokines and disease. Nat. Immunol. 2, 108-115.
47. Ghezzi, S., Noonan, D. M., Aluigi, M. G., Vallanti, G., Cota, M., Benelli, R., Morini, M., Reeves, J. D., Vicenzi, E., Poli, G., and Albini, A. (2000). Inhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 Tat. Biochem. Biophys. Res. Commun. 270, 992-996.
48. Goda, S., Imai, T., Yoshie, O., Yoneda, O., Inoue, H., Nagano, Y., Okazaki, T., Imai, H., Bloom, E. T., Domae, N., and Umehara, H. (2000). CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J. Immunol. 164, 4313-4320.
49. Gosling, J., Slaymaker, S., Gu, L., Tseng, S., Zlot, C. H., Young, S. G., Rollins, B. J., and Chard, I. F. (1999). MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. 103, 773-778.
50. Gu, L., Okada, Y., Clinton, S. K., Gerard, C., Sukhova, G. K., Libby, P., and Rollins, B. J. (1998). Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell 2, 275-281.
51. Gupta, S. K., and Pillarisetti, K. (1999). Cutting edge: CXCR4-Lo: Molecular cloning and functional expression of a novel human CXCR4 splice variant. J. Immunol. 163, 2368-2372.
52. Handel, T. M., and Domaille, P. J. (1996). Heteronuclear (1H, 13C, 15N) NMR assignments and solution structure of the monocyte chemoattractant protein-1 (MCP-1) dimer. Biochem. 35, 6569-6584.
53. Handel, T. M., and Lau, E. K. (2004). Chemokine structure and receptor interactions. Ernst. Schering. Res. Found Workshop 45, 101-124.
54. Hartley, O., Dorgham, K., Perez-Bercoff, D., Cerini, F., Heimann, A., Gaertner, H., Offord, R. E., Pancino, G., Debre, P., and Gorochov, G. (2003). Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines. J. Virol. 77, 6637-6644.
55. Haskell, C. A., Cleary, M. D., and Charo, I. F. (1999). Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J. Biol. Chem. 274, 10053-10058.
56. Hedrick, J. A., Saylor, V., Figueroa, D., Mizoue, L., Xu, Y., Menon, S., Abrams, J., Handel, T., and Zlotnik, A. (1997). Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo. J. Immunol. 158, 1533-1540.
57. Hemmerich, S., Paavola, C., Bloom, A., Bhakta, S., Freedman, R., Grunberger, D., Krstenansky, J., Lee, S., McCarley, D., Mulkins, M., Wong, B., Pease, J., Mizoue, L., Mirzadegan, T., Polsky, I., Thompson, K., Handel, T. M., and Jarnagin, K. (1999). Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2. Biochem. 38, 13013-13025.
58. Hernanz-Falcon, P., Rodriguez-Frade, J. M., Serrano, A., Juan, D., del Sol, A., Soriano, S. F., Roncal, F., Gomez, L., Valencia, A., Martinez, A. C., and Mellado, M. (2004). Identification of amino acid residues crucial for chemokine receptor dimerization. Nat. Immunol. 5, 216-223.
59. Ho, H. H., Du, D., and Gershengorn, M. C. (1999). The N terminus of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor is necessary for high affinity chemokine binding but not for constitutive activity. J. Biol. Chem. 274, 31327-31332.
60. Holst, P. J., Rosenkilde, M. M., Manfra, D., Chen, S. C., Wiekowski, M. T., Holst, B., Cifire, F., Lipp, M., Schwartz, T. W., and Lira, S. A. (2001). Tumorigenesis induced by the HHV8-encoded chemokine receptor requires ligand modulation of high constitutive activity. J. Clin. Invest. 108, 1789-1796.
61. Homey, B., Muller, A., and Zlotnik, A. (2002). Chemokines: Agents for the immunotherapy of cancer? Nat. Rev. Immunol. 2, 175-184.
62. Hoogewerf, A. J., Kuschert, G. S., Proudfoot, A. E., Borlat, F., Clark-Lewis, I., Power, C. A., and Wells, T. N. (1997). Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochem. 36, 13570-13578.
63. Hoover, D. M., Boulegue, C., Yang, D., Oppenheim, J. J., Tucker, K., Lu, W., and Lubkowski, J. (2002). The structure of human macrophage inflammatory protein-3alpha/CCL20. Linking antimicrobial and CC chemokine receptor-6-binding activities with human beta-defensins. J. Biol. Chem. 277, 37647-37654.
64. Hoover, D. M., Mizoue, L. S., Handel, T. M., and Lubkowski, J. (2000). The crystal structure of the chemokine domain of fractalkine shows a novel quaternary arrangement. J. Biol. Chem. 275, 23187-23193.
65. Horuk, R. (2003). Development and evaluation of pharmacological agents targeting chemokine receptors. Methods 29, 369-375.
66. Horuk, R., and Ng, H. P. (2000). Chemokine receptor antagonists. Med. Res. Rev. 20, 155-168.
67. Houshmand, P., and Zlotnik, A. (2003). Therapeutic applications in the chemokine superfamily. Curr. Opin. Chem. Biol. 7, 457-460.
68. Jarnagin, K., Grunberger, D., Mulkins, M., Wong, B., Hemmerich, S., Paavola, C., Bloom, A., Bhakta, S., Diehl, F., Freedman, R., McCarley, D., Polsky, I., Ping-Tsou, A., Kosaka, A., and Handel, T. M. (1999). Identification of surface residues of the monocyte chemotactic protein 1 that affect signaling through the receptor CCR2. Biochem. 38, 16167-16177.
69. Jensen, K. K., Chen, S. C., Hipkin, R. W., Wiekowski, M. T., Schwarz, M. A., Chou, C. C., Simas, J. P., Alcami, A., and Lira, S. A. (2003). Disruption of CCL21-induced chemotaxis in vitro and in vivo by M3, a chemokine-binding protein encoded by murine gammaherpesvirus 68. J. Virol. 77, 624-630.
70. Johnson, Z., Kosco-Vibois, M., Herren, S., Cirillo, R., Muzio, V., Smailbegovis, A., Rose, M., Lever, R., Page, C., Wells, T., and Proudfoot, A. E. I. (2004). Interference with heparin binding and oligomerization creates a novel antiinflammatory strategy targeting the chemokine system. Proc. Natl. Acad. Sci. USA, submitted.
71. Katancik, J. A., Sharma, A., Radel, S. J., and De Nardin, E. (1997). Mapping of the extracellular binding regions of the human interleukin-8 type B receptor. Biochem. Biophys. Res. Commun. 232, 663-668.
72. Keiser, N., Venkataraman, G., Shriver, Z., and Sasisekharan, R. (2001). Direct isolation and sequencing of specific protein-binding glycosaminoglycans. Nat. Med. 7, 123-128.
73. Kim, K. S., Rajarathnam, K., Clark-Lewis, I., and Sykes, B. D. (1996). Structural characterization of a monomeric chemokine: Monocyte chemoattractant protein-3. FEBS Lett. 395, 277-282.
74. Kim, S., Jao, S., Laurence, J. S., and LiWang, P. J. (2001). Structural comparison of monomeric variants of the chemokine MIP-1 beta having differing ability to bind the receptor CCR5. Biochem. 40, 10782-10791.
75. Kitamoto, S., and Egashira, K. (2002). Gene therapy targeting monocyte chemoattractant protein-1 for vascular disease. J. Atheroscler. Thromb. 9, 261-265.
76. Kuloglu, E. S., McCaslin, D. R., Kitabwalla, M., Pauza, C. D., Markley, J. L., and Volkman, B. F. (2001). Monomeric solution structure of the prototypical 'C' chemokine lymphotactin. Biochem. 40, 12486-12496.
77. Kunkel, E., and Butcher, E. (2002). Homeostatic chemokines and the targeting of regional immunity. Adv. Exp. Med. Biol. 512, 65-72.
78. Kuschert, G. S. V., Coulin, F., Power, C. A., Proudfoot, A. E. I., Hubbard, R. E., Hoogewerf, A. J., and Wells, T. N. C. (1999). Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Bio. Chem. 38, 12959-12968.
79. Lau, E. K., Kungl, A., Paavola, C., Johnson, Z., Borlat, F., Proudfoot, A. E. I., and Handel, T. M. (2004). Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1; Implications for structure and function in vivo. J. Biol. Chem 279, 22294-305.
80. Liu, D., Shriver, Z., Qi, Y., Venkataraman, G., and Sasisekharan, R. (2002). Dynamic regulation of tumor growth and metastasis by heparan sulfate glycosaminoglycans. Semin. Thromb. Hemost. 28, 67-78.
81. Liwang, A. C., Wang, Z. X., Sun, Y., Peiper, S. C., and Liwang, P. J. (1999). The solution structure of the anti-HIV chemokine vMIP-II. Protein. Sci. 8, 2270-2280.
82. Lodi, P. J., Garrett, D. S., Kuszewski, J., Tsang, M. L., Weatherbee, J. A., Leonard, W. J., Gronenborn, A. M., and Clore, G. M. (1994). High-resolution solution structure of the beta chemokine hMIP-1 beta by multidimensional NMR. Science 263, 1762-1767.
83. Loetscher, P., and Clark-Lewis, I. (2001). Agonistic and antagonistic activities of chemokines. J. Leukoc. Biol. 69, 881-884.
84. Loetscher, P., Pellegrino, A., Gong, J. H., Mattioli, I., Loetscher, M., Bardi, G., Baggiolini, M., and Clark-Lewis, I. (2001). The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J. Biol. Chem. 276, 2986-2991.
85. Lubkowski, J., Bujacz, G., Boque, L., Domaille, P. J., Handel, T. M., and Wlodawer, A. (1997). The structure of MCP-1 in two crystal forms provides a rare example of variable quaternary interactions. Nat. Struct. Biol. 4, 64-69.
86. Mantovani, A. (1999). The chemokine system: Redundancy for robust outputs. Immunol. Today 20, 254-257.
87. Mayer, K. L., and Stone, M. J. (2000). NMR solution structure and receptor peptide binding of the CC chemokine eotaxin-2. Biochem. 39, 8382-8395.
88. Mellado, M., Martinez, A. C., Rodriguez-Frade, J. M., Vila-Coro, A. J., Martinez, C., and Manes, S. (2002). Analysis of G-protein-coupled receptor dimerization following chemokine signaling. Methods 27, 349-357.
89. Mellado, M., Rodriguez-Frade, J. M., Vila-Coro, A. J., Fernandez, S., Martin de Ana, A., Jones, D. R., Toran, J. L., and Martinez, A. C. (2001). Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J. 20, 2497-2507.
90. Mellado, M., Vila-Coro, A. J., Martinez, C., Rodriguez-Frade, J. M., Manes, S., and Martinez, A. C. (2001). Receptor dimerization: A key step in chemokine signaling. Cell Mol. Biol. (Noisy-le-grand) 47, 575-582.
91. Middleton, J., Neil, S., Wintle, J., Clark-Lewis, I., Moore, H., Lam, C., Auer, M., Hub, E., and Rot, A. (1997). Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 91, 385-395.
92. Middleton, J., Patterson, A. M., Gardner, L., Schmutz, C., and Ashton, B. A. (2002). Leukocyte extravasation: Chemokine transport and presentation by the endothelium. Blood 100, 3853-3860.
93. Mirzadegan, T., Diehl, F., Ebi, B., Bhakta, S., Polsky, I., McCarley, D., Mulkins, M., Weatherhead, G. S., Lapierre, J. M., Dankwardt, J., Morgans, D., Jr., Wilhelm, R., and Jarnagin, K. (2000). Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: Binding to a common chemokine receptor motif within the helical bundle. J. Biol. Chem. 275, 25562-25571.
94. Mizoue, L. S., Bazan, J. F., Johnson, E. C., and Handel, T. M. (1999). Solution structure and dynamics of the CX3C chemokine domain of fractalkine and its interaction with an N-terminal fragment of CX3CR1. Biochemistry 38, 1402-1414.
95. Monteclaro, F. S., and Charo, I. F. (1997). The amino-terminal domain of CCR2 is both necessary and sufficient for high affinity binding of monocyte chemoattractant protein 1. Receptor activation by a pseudo-tethered ligand. J. Biol. Chem. 272, 23186-23190.
96. Moser, B., Dewald, B., Barella, L., Schumacher, C., Baggiolini, M., and Clark-Lewis, I. (1993). Interleukin-8 antagonists generated by N-terminal modification. J. Biol. Chem. 268, 7125-7128.
97. Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., Barrera, J. L., Mohar, A., Verastegui, E., and Zlotnik, A. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56.
98. Muller, G., Hopken, U. E., and Lipp, M. (2003). The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Concerted action of the chemokine and lymphotoxin system in secondary lymphoid-organ development. Immunol. Rev. 195, 117-135.
99. Murphy, P. M. (1994). The molecular biology of leukocyte chemoattractant receptors. Annu. Rev. Immunol. 12, 593-633.
100. Murphy, P. M. (2001). Chemokines and the molecular basis of cancer metastasis. N. Engl. J. Med. 345, 833-835.
101. Murphy, P. M. (2001). Viral exploitation and subversion of the immune system through chemokine mimicry. Nat. Immunol. 2, 116-122.
102. Murphy, P. M., Baggiolini, M., Charo, I. F., Hebert, C. A., Horuk, R., Matsushima, K., Miller, L. H., Oppenheim, J. I., and Power, C. A. (2000). International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52, 145-176.
103. Nash, P., Barrett, J., Cao, J. X., Hota-Mitchell, S., Lalani, A. S., Everett, H., Xu, X. M., Robichaud, J., Hnatiuk, S., Ainslie, C., Seet, B. T., and McFadden, G. (1999). Immunomodulation by viruses: The myxoma virus story. Immunol. Rev. 168, 103-120.
104. Noonan, D., and Albini, A. (2000). From the outside in: Extracellular activities of HIV Tat. Adv. Pharmacol. 48, 229-250.
105. Ogilvie, P., Bardi, G., Clark-Lewis, I., Baggiolini, M., and Uguccioni, M. (2001). Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood 97, 1920-1924.
106. Ogilvie, P., Paoletti, S., Clark-Lewis, I., and Uguccioni, M. (2003). Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes. Blood 102, 789-794.
107. Olson, T. S., and Ley, K. (2002). Chemokines and chemokine receptors in leukocyte trafficking. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283, R7-R28.
108. Ono, S. J., Nakamura, T., Miyazaki, D., Ohbayashi, M., Dawson, M., and Toda, M. (2003). Chemokines: Roles in leukocyte development, trafficking, and effector function. J. Allergy Clin. Immunol. 111, 1185-1199; quiz 1200.
109. Onuffer, J., McCarrick, M. A., Dunning, L., Liang, M., Rosser, M., Wei, G. P., Ng, H., and Horuk, R. (2003). Structure function differences in nonpeptide CCR1 antagonists for human and mouse CCR1. J. Immunol. 170, 1910-1916.
110. Onuffer, J. J., and Horuk, R. (2002). Chemokines, chemokine receptors and small-molecule antagonists: Recent developments. Trends Pharmacol. Sci. 23, 459-467.
111. Paavola, C. D., Hemmerich, S., Grunberger, D., Polsky, I., Bloom, A., Freedman, R., Mulkins, M., Bhakta, S., McCarley, D., Wiesent, L., Wong, B., Jarnagin, K., and Handel, T. M. (1998). Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and activates the MCP-1 receptor CCR2B. J. Biol. Chem. 273, 33157-33165.
112. Pakianathan, D. R., Kuta, E. G., Artis, D. R., Skelton, N. J., and Hebert, C. A. (1997). Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5. Biochemistry 36, 9642-9648.
113. Patel, D. D., Koopmann, W., Imai, T., Whichard, L. P., Yoshie, O., and Krangel, M. S. (2001). Chemokines have diverse abilities to form solid phase gradients. Clin. Immunol. 99, 43-52.
114. Perez-Canadillas, J. M., Zaballos, A., Gutierrez, J., Varona, R., Roncal, F., Albar, J. P., Marquez, G., and Bruix, M. (2001). NMR solution structure of murine CCL20/MIP-3alpha, a chemokine that specifically chemoattracts immature dendritic cells and lymphocytes through its highly specific interaction with the beta-chemokine receptor CCR6. J. Biol. Chem. 276, 28372-28379.
115. Preobrazhensky, A. A., Dragan, S., Kawano, T., Gavrilin, M. A., Gulina, I. V., Chakravarty, L., and Kolattukudy, P. E. (2000). Monocyte chemotactic protein-1 receptor CCR2B is a glycoprotein that has tyrosine sulfation in a conserved extracellular N-terminal region. J. Immunol. 165, 5295-5303.
116. Proudfoot, A. E. (2002). Chemokine receptors: Multifaceted therapeutic targets. Nat. Rev. Immunol. 2, 106-115.
117. Proudfoot, A. E., Power, C. A., Hoogewerf, A. J., Montjovent, M. O., Borlat, F., Offord, R. E., and Wells, T. N. (1996). Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol. Chem. 271, 2599-2603.
118. Proudfoot, A. E. I., Handel, T. M., Johnson, Z., Lau, E. K., LiWang, P., Clark-Lewis, I., Borlat, F., Wells, T. N. C., and Kosco-Vilbois, M. H. (2003). Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc. Natl. Acad. Sci. USA 100, 1885-1890.
119. Quan, J. M., Martin, T. R., Rosenberg, G. B., Foster, D. C., Whitmore, T., and Goodman, R. B. (1996). Antibodies against the N-terminus of IL-8 receptor A inhibit neutrophil chemotaxis. Biochem. Biophys. Res. Commun. 219, 405-411.
120. Rajarathnam, K., Li, Y., Rohrer, T., and Gentz, R. (2001). Solution structure and dynamics of myeloid progenitor inhibitory factor-1 (MPIF-1), a novel monomeric CC chemokine. J. Biol. Chem. 276, 4909-1916.
121. Rajarathnam, K., Sykes, B. D., Kay, C. M., Dewald, B., Geiser, T., Baggiolini, M., and Clark-Lewis, I. (1994). Neutrophil activation by monomeric interleukin-8. Science 264, 90-92.
122. Rodriguez-Frade, J. M., Mellado, M., and Martinez, A. C. (2001). Chemokine receptor dimerization: Two are better than one. Trends Immunol. 22, 612-617.
123. Rollins, B. J. (2001). Chemokines and atherosclerosis: What Adam Smith has to say about vascular disease. J. Clin. Invest. 108, 1269-1271.
124. Rosenkilde, M. M., Waldhoer, M., Luttichau, H. R., and Schwartz, T. W. (2001). Virally encoded 7TM receptors. Oncogene 20, 1582-1593.
125. Rot, A. (1993). Neutrophil attractant/activation protein-1 (interleukin-8) induces in vitro neutrophil migration by haptotactic mechanism. Eur. J. Immunol. 23, 303-306.
126. Sanchez-Madrid, F., and del Pozo, M. A. (1999). Leukocyte polarization in cell migration and immune interactions. EMBO J. 18, 501-511.
127. Sasisekharan, R., Shriver, Z., Venkataraman, G., and Narayanasami, U. (2002). Roles of heparan-sulphate glycosaminoglycans in cancer. Nat. Rev. Cancer 2, 521-528.
128. Seet, B. T., Johnston, J. B., Brunetti, C. R., Barrett, J. W., Everett, H., Cameron, C., Sypula, J., Nazarian, S. H., Lucas, A., and McFadden, G. (2003). Poxviruses and immune evasion. Annu. Rev. Immunol. 21, 377-423.
129. Shimaoka, T., Nakayama, T., Fukumoto, N., Kume, N., Takahashi, S., Yamaguchi, J., Minami, M., Hayashida, K., Kita, T., Ohsumi, J., Yoshie, O., and Yonehara, S. (2004). Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J. Leukoc. Biol. 75, 267-274.
130. Shriver, Z., Liu, D., and Sasisekharan, R. (2002). Emerging views of heparan sulfate glycosaminoglycan structure/activity relationships modulating dynamic biological functions. Trends Cardiovasc. Med. 12, 71-77.
131. Sica, A., Saccani, A., and Mantovani, A. (2002). Tumor-associated macrophages: A molecular perspective. Int. Immunopharmacol. 2, 1045-1054.
132. Signoret, N., Pelchen-Matthews, A., Mack, M., Proudfoot, A. E., and Marsh, M. (2000). Endocytosis and recycling of the HIV coreceptor CCR5. J. Cell Biol. 151, 1281-1294.
133. Simmons, G., Clapham, P. R., Picard, L., Offord, R. E., Rosenkilde, M. M., Schwartz, T. W., Buser, R., Wells, T. N., and Proudfoot, A. E. (1997). Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276, 276-279.
134. Simmons, G., Reeves, J. D., Hibbitts, S., Stine, J. T., Gray, P. W., Proudfoot, A. E., and Clapham, P. R. (2000). Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol. Rev. 177, 112-126.
135. Skelton, N. J., Aspiras, F., Ogez, J., and Schall, T. J. (1995). Proton NMR assignments and solution conformation of RANTES, a chemokine of the C-C type. Biochemistry 34, 5329-5342.
136. Skelton, N. J., Quan, C., Reilly, D., and Lowman, H. (1999). Structure of a CXC chemokine-receptor fragment in complex with interleukin-8. Structure Fold Des. 7, 157-168.
137. Springer, T. A. (1994). Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 76, 301-314.
138. Springer, T. A. (1995). Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Annu. Rev. Physiol. 57, 827-872.
139. Stringer, S. E., Forster, M. J., Mulloy, B., Bishop, C. R., Graham, G. J., and Gallagher, J. T. (2002). Characterization of the binding site on heparan sulfate for macrophage inflammatory protein 1alpha. Blood 100, 1543-1550.
140. Stringer, S. E., and Gallagher, J. T. (1997). Specific binding of the chemokine platelet factor 4 to heparan sulfate. J. Biol. Chem. 272, 20508-20514.
141. Struyf, S., Proost, P., and Van Damme, J. (2003). Regulation of the immune response by the interaction of chemokines and proteases. Adv. Immunol. 81, 1-44.
142. Sundaram, M., Qi, Y. W., Shriver, Z., Liu, D. F., Zhao, G. L., Venkataraman, G., Langer, R., and Sasisekharan, R. (2003). Rational design of low-molecular weight heparins with improved in vivo activity. Proc. Natl. Acad. Sci. USA 100, 651-656.
143. Suzuki, H., Prado, G. N., Wilkinson, N., and Navarro, J. (1994). The N terminus of interleukin-8 (IL-8) receptor confers high affinity binding to human IL-8. J. Biol. Chem. 269, 18263-18266.
144. Swaminathan, G. J., Holloway, D. E., Colvin, R. A., Campanella, G. K., Papageorgiou, A. C., Luster, A. D., and Acharya, K. R. (2003). Crystal structures of oligomeric forms of the IP-10/CXCL10 chemokine. Structure (Camb) 11, 521-532.
145. Terrillon, S., and Bouvier, M. (2004). Roles of G-protein-coupled receptor dimerization. EMBO Rep. 5, 30-34.
146. Thelen, M. (2001). Dancing to the tune of chemokines. Nat. Immunol. 2, 129-134.
147. Thelen, M., and Baggiolini, M. (2001). Is dimerization of chemokine receptors functionally relevant? Sci. STKE 2001, PE34.
148. van Berkel, V., Barrett, J., Tiffany, H. L., Fremont, D. H., Murphy, P. M., McFadden, G., Speck, S. H., and Virgin, H. I. (2000). Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J. Virol. 74, 6741-6747.
149. Vene, R., Benelli, R., Noonan, D. M., and Albini, A. (2000). HIV-Tat dependent chemotaxis and invasion, key aspects of tat mediated pathogenesis. Clin. Exp. Metastasis 18, 533-538.
150. Vicari, A. P., and Caux, C. (2002). Chemokines in cancer. Cytokine Growth Factor Rev. 13, 143-154.
151. Weber, C. (2003). Novel mechanistic concepts for the control of leukocyte transmigration: Specialization of integrins, chemokines, and junctional molecules. J. Mol. Med. 81, 4-19.
152. Weber, M., Uguccioni, M., Baggiolini, M., Clark-Lewis, I., and Dahinden, C. A. (1996). Deletion of the NH2-terminal residue converts monocyte chemotactic protein 1 from an activator of basophil mediator release to an eosinophil chemoattractant. J. Exp. Med. 183, 681-685.
153. Wells, T. N., Power, C. A., Lusti-Narasimhan, M., Hoogewerf, A. J., Cooke, R. M., Chung, C. W., Peitsch, M. C., and Proudfoot, A. E. (1996). Selectivity and antagonism of chemokine receptors. J. Leukoc. Biol. 59, 53-60.
154. Wells, T. N., and Schwartz, T. W. (1997). Plagiarism of the host immune system: Lessons about chemokine immunology from viruses. Curr. Opin. Biotechnol. 8, 741-748.
155. Wu, L., Ruffing, N., Shi, X., Newman, W., Soler, D., Mackay, C. R., and Oin, S. (1996). Discrete steps in binding and signaling of interleukin-8 with its receptor. J. Biol. Chem. 271, 31202-31209.
156. Xanthou, G., Williams, T. J., and Pease, J. E. (2003). Molecular characterization of the chemokine receptor CXCR3: Evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation. Eur. J. Immunol. 33, 2927-2936.
157. Ye, J., Mayer, K. L., Mayer, M. R., and Stone, M. J. (2001). NMR solution structure and backbone dynamics of the CC chemokine eotaxin-3. Biochem. 40, 7820-7831.
158. Zhang, X., Chen, L., Bancroft, D. P., Lai, C. K., and Maione, T. E. (1994). Crystal structure of recombinant human platelet factor 4. Biochem. 33, 8361-8366.
159. Zhang, Y., and Rollins, B. J. (1995). A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer. Mol. Cell. Biol. 15, 4851-4855.
160. Zlotnik, A. (2004). Chemokines and cancer. Ernst. Schering. Res. Found Workshop 53-58.
161. Zoffmann, S., Chollet, A., and Galzi, J. L. (2002). Identification of the extracellular loop 2 as the point of interaction between the N terminus of the chemokine MIP-1alpha and its CCR1 receptor. Mol. Pharmacol. 62, 729-736.